The figure Merqurio invented. First misunderstood, then opposed, finally imitated.
Scientific information by phone, web and webcam. A Merqurio registered trademark.
The doctor stays updated when and how they want. Information must follow them.
Over a third of doctors browse DottNet between 8pm and 8am: hours when a face-to-face visit is unthinkable. The doctor manages their updating in their own time, between PC and mobile, when it is most convenient. Face-to-face information, on its own, no longer intercepts these moments.
The Informatore Remoto® — born at Merqurio in the 1990s — is the answer: a scientific rep who operates by phone and web, an alternative or support to the face-to-face visit, which makes it possible to eliminate unproductive expenses and to reach the doctor when they are available. Not a call centre: a pharma professional, with the same competences as the field rep.
Scientific information by phone, web and video call, with branded content and call scripts adapted to the individual doctor's journey.
Facilitated access for the doctor via DottNet credentials, with a significant increase in video calls made.
Real-time tracking of the doctor's online activity in the campaign, to centre the relationship on their real interests.
Information on mature products, sales-force support, notices on product changes, lead generation and appointment acquisition, increased subscriptions to restricted areas.
Remote covers those the field network does not reach.
A remote call between one field visit and the next keeps the relationship alive.
Remote garrisons products that do not justify a dedicated field visit.
Remote reaches more doctors at a lower cost than field alone.
The Informatore Remoto® is not a service Merqurio bought or copied: it invented it. This means competence, process and technology built on thirty years of practice, not on a recent adaptation.
The proprietary database targets doctors and the integration with DottNet facilitates access. The figure is a pharma professional, trained and integrated into the pharmacovigilance process.
